
    
      This is an open-label, multi-center, cross-over study in male and female pediatric cancer
      patients, aged 2 to 5 years who are receiving at least 2 cycles of emetogenic chemotherapy
      requiring 5-HT3 antagonist treatment of up to 5 days duration. The study is designed to
      evaluate the safety and PK of transdermal granisteron (Sancuso(R) patch) in a pediatric
      population (aged 2 to 5 years) using a population PK approach.
    
  